达格列净对2型糖尿病并发非酒精性脂肪性肝病患者肝功能的改善作用及其机制

doi:10.13481/j.1671-587x.20200120

Abstract

Abstract: Objective: To investigate the effect of dapagliflozin on the liver function of the patients with type 2 diabetes mellitus (T2DM) complicated with non-alcoholic fatty liver disease (NAFLD), and to analyze its improvement effect on liver injury of the T2DM patients. Methods: The clinical data of 68 T2DM patients complicated with NAFLDS who did not receive any treatment were retrospectively analyzed, including 30 patients in acarbose group and 38 patients in dapagliflozin group, and the patients in two groups received acarbose 150 mg·d^-1+ metformin 2 000 mg·d^-1 and dapagliflozin 10 mg·d^-1 + metformin 2 000 mg·d^-1 treatment for 24 weeks, respectively. The general data of the patients before and after treatment were collected.The fasting venous blood of the patients in two groups was collected and the serum biochemical indexes and liver function indexes were detected.The serum biochemical indexes included fasting blood glucose(FBG) and glycosylated hemoglobin (HbA1c),and the homeostasis model assessment 2-insulin resistance index(HMOA2-IR) was calculated.The liver function indexes included aspartic transaminase (AST), alanine aminotransferase (ALT), glutamyltranspeptidase (GGT), alkaline phosphatase (ALP), total bilirubin (TBIL),and direct bilirubin (DBIL);the non-alcoholic fatty liver disease fibrosis score (NAFLDFS) was calculated.The each detection index of the patients in two groups was compared and analyzed. Results: Compared with before treatment, the levels of FBG, HbA1c, AST, GGT, and ALP and HOMA2-IR in acarbose group after treatment were significantly decreased(P<0.01) and the levels of TBIL was significantly increased (P<0.01). Compared with before treatment, the levels of FBG, HbA1c, AST, ALT, GGT, and ALP and HOMA2-IR,NAFLDFS in dapagliflozin group were significantly decreased after treatment (P<0.01) and the levels of TBIL and DBIL were significantly increased (P<0.01). The levels of FBG, AST, ALT, GGT, and ALP and NAFLDF in dapagliflozin group after treatment were significantly decreased compared with acarbose group (P<0.01). Conclusion: Dagliflozin can improve the liver function of the patients with T2DM complicated with NAFLD, and its mechanism may be related to the effect of dapagliflozin decreasing the blood glucose and body weight.

Key words: dapagliflozin, type 2 diabetes, non-alcoholic fatty liver disease, liver function

CLC Number:

R587.1

SUN Yuanyuan, LIANG Li, WANG Xiaoye, XIAO Yan, GAO Ying. Improvement effect of dapagliflozin on liver function in patients with type 2 diabetes mellitus complicated with non-alcoholic fatty liver diseaseand itsmechanism[J].Journal of Jilin University(Medicine Edition), 2020, 46(01): 116-120.

References

[1] ADAMS L A, ANSTEE Q M, TILG H, et al. Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases[J]. Gut, 2017, 66(6):1138-1153.
[2] ALEXANDER K S, ZAKAI N L, LIDOFSKY S D, et al. Non-alcoholic fatty liver disease, liver biomarkers and stroke risk:The reasons for geographic and racial differences in stroke cohort[J]. PLoS One, 2018, 13(3):e0194153.
[3] KIM D, TOUROS A, KIM W R. Nonalcoholic fatty liver disease and metabolic syndrome[J]. Clin Liver Dis,2018, 22(1):133-140.
[4] BALLESTRI S, NASCIMBENI F, ROMAGNOLI D, et al. Type 2 diabetes in non-alcoholic fatty liver disease and hepatitis C virus infection-liver:The "Musketeer" in the spotlight[J]. Int J Mol Sci, 2016,17(3):355.
[5] SUNNY N E, BRIL F, CUSI K. Mitochondrial adaptation in nonalcoholic fatty liver disease:novel mechanisms and treatment strategies[J]. Trends Endocrinol Metab, 2017, 28(4):250-260.
[6] HONDA Y, IMAJO K, KATO T, et al. The selective SGLT2 inhibitor Ipragliflozin has a therapeutic effect on nonalcoholic steatohepatitis in mice[J]. PLoS One, 2016, 11(1):e0146337.
[7] ROMEO S, KOZLITINA J, XING C, et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease[J]. Nat Genet, 2008, 40(12):1461-1465.
[8] KOLIAKI C, SZENDROEDI J, KAUL K, et al. Adaptation of hepatic mitochondrial function in humans with non-alcoholic fatty liver is lost in steatohepatitis[J]. Cell Metab, 2015, 21(5):739-746.
[9] BOLINDER J, LJUNGGREN Ö, JOHANSSON L, et al. Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin[J]. Diabetes Obes Metab, 2014, 16(2):159-169.
[10] SUISSA S. Lower risk of death with SGLT2 inhibitors in observational studies:real or bias?[J]. Diabetes Care, 2018,41(1):6-10.
[11] YOUNOSSI Z M, KOENIG A B, ABDELATIF D, et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes[J]. Hepatology, 2016, 64(1):73-84.
[12] LOMBARDI R, ONALI S, THORBURN D, et al. Pharmacological interventions for non-alcohol related fatty liver disease (NAFLD):An attempted network meta-analysis[J]. Cochrane Database Syst Rev, 2017, 3:CD011640.
[13] KWOK R, CHOI K C, WONG G L, et al. Screening diabetic patients for non-alcoholic fatty liver disease with controlled attenuation parameter and liver stiffness measurements:A prospective cohort study[J]. Gut, 2016, 65(8):1359-1368.
[14] ADAMS L A, HARMSEN S, STSAUVER J L, et al. Nonalcoholic fatty liver disease increases risk of death among patients with diabetes:A community-based cohort study[J]. Am J Gastroenterol,2010, 105(7):1567-1573.
[15] EL-SERAG H B, HAMPEL H, JAVADI F. The association between diabetes and hepatocellular carcinoma:A systematic review of epidemiologic evidence[J]. Clin Gastroenterol Hepatol, 2006, 4(3):369-380.
[16] NEUSCHWANDER-TETRI B A, LOOMBA R, SANYAL A J, et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT):A multicentre, randomised, placebo-controlled trial[J]. Lancet, 2015, 385(9972):956-965.
[17] MOTA M, BANINI B A, CAZANAVE S C, et al. Molecular mechanisms of lipotoxicity and glucotoxicity in nonalcoholic fatty liver disease[J]. Metab Clin Exp, 2016, 65(8):1049-1061.
[18] WANG D, LUO Y H, WANG X X, et al. The sodium-glucose cotransporter 2 inhibitor Dapagliflozin prevents renal and liver disease in western diet induced obesity mice[J]. Int J Mol Sci, 2018, 19(1):E137.
[19] 舒筠然,李俊琪,刘琼.非酒精性脂肪性肝病的流行病学和危险因素分析[J]. 临床肝胆病杂志,2019, 35(9):2085-2090.

Improvement effect of dapagliflozin on liver function in patients with type 2 diabetes mellitus complicated with non-alcoholic fatty liver diseaseand itsmechanism

PDF (PC)

Like

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Metrics

Comments

Recommended 10

[1]	DU Xingxu, QIAO Zijing, YANG Shuo, XU Zhiying, YANG Bo, LI He, CHEN Jianguang, WANG Chunmei. Effect of Schisandra chinensis polysaccharide on serum inflammatory factors in T2DM rats and its mechanism [J]. Journal of Jilin University(Medicine Edition), 2020, 46(01): 50-55.
[2]	SONG Na, SU Dongfeng, LIU Xiaoyan, GAO Yu, LIU Chang, LI Lihui. Protective effect of soy isoflavone on oxidative stress injury in perimenopause model rats with type 2 diabetes mellitus [J]. Journal of Jilin University(Medicine Edition), 2019, 45(06): 1310-1314.
[3]	MIAO Xiangxia, GUO Rui, ZHANG Ying, WEI Yinyin, LUO Zhengqi, MIN Yali, LIU Kaige. Inhibitory effect of resveratrol on fat synthesis in liver cancer HepG₂ cells and its mechanism [J]. Journal of Jilin University(Medicine Edition), 2019, 45(01): 69-72.
[4]	QI Lu, BAI Wei, YU Weiying, LI Yuanyuan, HUA Wanqing, KOU Changgui. Randomized controlled trials for curative effect of saxagliptin combined with insulin in treatment of patients with type 2 diabetes mellitus: Meta-analysis [J]. Journal of Jilin University(Medicine Edition), 2018, 44(06): 1235-1242.
[5]	QI Bingxue, SUN Yadong. A prospective study on primary prevention of major vascular lesions of type 2 diabetes mellitus patients in Han population in Northeast China [J]. Journal of Jilin University(Medicine Edition), 2018, 44(06): 1243-1248.
[6]	SUN Zhumei, LIANG Weishi, KANG Jiali, MENG Xubing, WANG Jianxing, HAN Shuying. Dynamic pathological characteristics of kidney in db/db mice with type 2 diabetes mellitus [J]. Journal of Jilin University Medicine Edition, 2018, 44(03): 499-503.
[7]	LIU Xiaojie, MEI Tao, MA Hongyan, YE Shandong. Analysis of influencing factors of carotid atherosclerosis plaque formation and stability in simple type 2 diabetic patients [J]. Journal of Jilin University Medicine Edition, 2018, 44(02): 350-355.
[8]	LI Chunhua, GUO Xin, DOU Jing, DING Mingxuan, YAO Yan, ZHANG Yanqiu. Survey analysis on cognitive dysfunction in patients with type 2 diabetes mellitus and its influecing factors [J]. Journal of Jilin University Medicine Edition, 2018, 44(02): 431-437.
[9]	WANG Jianxing, JIANG Yan, WANG Yan, WU Lei, MU Yu, HAN Shuying. Influence of extract from fermented buckwheat flower and leaf in kidney injury in type 2 diabetic db/db mice [J]. Journal of Jilin University Medicine Edition, 2018, 44(01): 95-100.
[10]	YUAN Rongshuang, LI He, SUN Jinghui, ZHUANG Wenyue, CHEN Jianguang, WANG Chunmei. Lipid-lowering effect and antioxidant activity of polysaccharide from Schisandra Chinensis in rats with non-alcoholic fatty liver disease induced by high-fat diet [J]. Journal of Jilin University Medicine Edition, 2017, 43(06): 1103-1108.
[11]	HUO Lianguang, YAN Qingtao, YAN Jingyue, LI Na, SU Han, ZHANG Meijia, MAO Shumei, GAO Zhiqin, QU Meihua. Improvement effect of duodenal-jejunal bypass on inflammatory status of biliopancreatic limb of ZDF rats and its mechanism [J]. Journal of Jilin University Medicine Edition, 2017, 43(06): 1155-1160.
[12]	WEI Yanhong, SONG Shuai, GENG Hui, DIAO Binbin, YANG Guangmin. Clinical significance of detection of alpha 1-microglobulin in serum of patients with chronic hepatitis B [J]. Journal of Jilin University Medicine Edition, 2017, 43(01): 96-100.
[13]	GOU Xiangbo, GUO Jing, BAI Jing. Protective effect of total flavones of buckwheat flowers and leaves on myocardial fibrosis of type 2 diabetic ratsand its mechanism [J]. Journal of Jilin University Medicine Edition, 2016, 42(04): 694-698.
[14]	KONG Wenli, YANG Yiliang, XU Hongqin, PENG Shanshan, HUA Rui, PAN Yu, NIU Junqi. Relationship between liver functionand virological response in patients with chronic hepatitis C during antiviral treatment [J]. Journal of Jilin University Medicine Edition, 2016, 42(01): 99-103.
[15]	TU Peipei, LI Xiaodan, MA Baicheng, ZHANG Yaofang, DUAN Huikun, NI Zaizhong, WANG Haisong, JIANG Pingzhe, LI Miao, WU Ri, LI Minggang. Changes and significance of hepatic histone H3 epigenetic modification in type 2 diabetic mice [J]. Journal of Jilin University Medicine Edition, 2015, 41(04): 756-762.